ASX Share rice
Sun 16 May 2021 - 06:22:am (Sydney)

ACW Share Price

ACTINOGEN MEDICAL LIMITEDACWPharmaceuticals, Biotechnology & Life Sciences

ACW Company Information

Name:

Actinogen Medical Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

109 Pitt Street Sydney NSW Australia 2000

Phone:

61 2 8964 7401

MD, CEO & Director:

Dr. Steven G. Gourlay

Chief Financial Officer:

Mr. Jeff Carter

Company Sec.:

Mr. Peter Gordon Webse M.A.I.C.D., B.Bus, FGIA, FCIS, FCPA, MAICD

Company Overview:

Actinogen Medical Limited, a biotechnology company, develops therapies for cognitive impairment associated with chronic neurological, psychiatric, and metabolic diseases in Australia. The company is developing Xanamem, a therapy for Alzheimer's disease, and cognitive impairment associated with schizophrenia, diabetes, and other disorders; and XanADu, which has completed Phase II clinical trials is a double-blind, randomized, and placebo-controlled study to assess the safety, tolerability, and efficacy of Xanamem in subjects with mild Alzheimer's disease. It is also developing XanaHES, a single blinded, central reader blinded, placebo-controlled, and dose escalation study of Xanamem to assess safety and tolerability in healthy elderly subjects. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is headquartered in Sydney, Australia.

ACW Share Price Information

Shares Issued:

1.66B

Market Capitalisation:

$91.33M

Revenue (TTM):

$2.84M

Revenue Per Share (TTM):

$0

Earnings per Share:

$-0.009

Profit Margin:

-1.2827

Operating Margin (TTM):

$-1.31

Return On Assets (TTM):

$-0.16

Return On Equity (TTM):

$-0.26

Quarterly Revenue Growth (YOY):

-0.91

Gross Profit(TTM):

$3.52M

Diluted Earnings Per Share (TTM):

$-0.003

ACW CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$-22,760

Change To Liabilities:

$75.70K

Total Cashflow From Investing Activities:

$-22,760

Net Borrowings:

$-77,742

Net Income:

$-5,330,529

Total Cash From Operating Activities:

$-2,855,613

Depreciation:

$412.93K

Change To Account Receivables:

$1.77M

Capital Expenditures:

$22.76K

ACW Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-5,330,530

Net Income:

$-5,330,530

Operating Income:

$-5,301,640

Interest Expense:

$28.88K

Total Revenue:

$94.06K

ACW Balance Sheet

Balance Sheet Date:

2020-06-30

Intangible Assets:

$3.35M

Total Liabilities:

$1.05M

Total Stockholder Equity:

$10.89M

Other Current Liabilities:

$583.96K

Total Assets:

$11.94M

Common Stock:

$51.32M

Other Current Assets:

$400.85K

Retained Earnings:

$-44,526,846

Other Assets:

$35.27K

Cash:

$5.04M

Total Current Liabilities:

$743.82K

Property - Plant & Equipment:

$391.04K

Net Tangible Assets:

$7.54M

Total Current Assets:

$8.16M

Net Receivables:

$2.66M

Short-Term Investments:

$3.77M

Accounts Payable:

$46.84K

Short-Term Investments:

$3.77

Non Current Liabilities Total:

$303.85K

ACW Share Price History

ACW News

27 Mar, 2021
Unfortunately, investing is risky - companies can and do go bankrupt. But if you pick the right business to buy shares...
23 Dec, 2020
Bill Ketelbey became the CEO of Actinogen Medical Limited ( ASX:ACW ) in 2014, and we think it's a good time to look at...
24 Sep, 2020
We can readily understand why investors are attracted to unprofitable companies. Indeed, Actinogen Medical (ASX:ACW...